819 related articles for article (PubMed ID: 15516022)
1. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
Li H; Butler K; Yang L; Yang Z; Teng R
Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
Teng R; Butler K
Eur J Clin Pharmacol; 2010 May; 66(5):487-96. PubMed ID: 20091161
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men.
van Troostenburg AR; Lee D; Jones TR; Dyck-Jones JA; Silverman MH; Lam GN; Warrington SJ
Int J Clin Pharmacol Ther; 2004 May; 42(5):253-9. PubMed ID: 15176647
[TBL] [Abstract][Full Text] [Related]
9. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
11. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
13. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
17. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Silverman MH; Strand V; Markovits D; Nahir M; Reitblat T; Molad Y; Rosner I; Rozenbaum M; Mader R; Adawi M; Caspi D; Tishler M; Langevitz P; Rubinow A; Friedman J; Green L; Tanay A; Ochaion A; Cohen S; Kerns WD; Cohn I; Fishman-Furman S; Farbstein M; Yehuda SB; Fishman P
J Rheumatol; 2008 Jan; 35(1):41-8. PubMed ID: 18050382
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
[TBL] [Abstract][Full Text] [Related]
19. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Avni I; Garzozi HJ; Barequet IS; Segev F; Varssano D; Sartani G; Chetrit N; Bakshi E; Zadok D; Tomkins O; Litvin G; Jacobson KA; Fishman S; Harpaz Z; Farbstein M; Yehuda SB; Silverman MH; Kerns WD; Bristol DR; Cohn I; Fishman P
Ophthalmology; 2010 Jul; 117(7):1287-93. PubMed ID: 20304499
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
